ETFs Holding ARQL »    ARQL Historical Stock Prices »
ARQL News Video: Fri, Nov 17, 2017, 1:52 PM — Daily Dividend Report: NKE, SYY, KEY, HD, BLK, FDX, KMB, ALL

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ArQule is a biopharmaceutical company engaged in the research and development of therapeutics to treat cancers and rare diseases. Co.'s pipeline includes: ARQ 087, which is in Phase 2 for intrahepatic cholangiocarcinoma and in Phase 1b for multiple oncology indications; ARQ 092, which is in Phase 1 for multiple oncology indications and in the rare disease, Proteus syndrome; ARQ 751, which is in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation; ARQ 531, which is for both wild type and C481S-mutant Bruton's tyrosine kinase; and ARQ 761, which is in Phase 1/2 in multiple oncology indications. Self directed investors in ArQule Inc. will be interested in keeping up with all ArQule Inc. news they can find, both ARQL news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ARQL. At RediNews, we simplify this task by presenting both ARQL news releases originating from ArQule Inc. itself, and ARQL news from a variety of media outlets. Visitors can browse this news online and through our ARQL RSS news feed.


ARQL News — Articles, Videos, & Press Releases

ArQule (ARQL) Catches Eye: Stock Moves 7.2% Higher
Friday, January 13, 2017, 7:00 AM — Zacks
Can The Uptrend Continue for ArQule (ARQL)?
Wednesday, September 28, 2016, 9:03 AM — Zacks
Tesaro Gets Fast Track Designation for Ovarian Cancer Drug
Tuesday, September 13, 2016, 11:35 AM — Zacks
The Medicines Co.'s Carbavance Scores in Phase III Study
Tuesday, June 28, 2016, 8:45 AM — Zacks
ArQule (ARQL) Shows Strength: Stock Adds 8% in Session
Thursday, June 23, 2016, 6:25 AM — Zacks
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Wednesday, June 8, 2016, 9:24 AM — Zacks
Catalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus
Wednesday, May 11, 2016, 1:29 PM — Zacks
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Wednesday, May 11, 2016, 7:01 AM — Zacks
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Wednesday, May 11, 2016, 6:10 AM — Zacks
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Wednesday, May 11, 2016, 5:49 AM — Zacks
ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Wednesday, May 11, 2016, 5:47 AM — Zacks
Valeant (VRX) Receives Notice of Default: Stock in Trouble?
Wednesday, April 13, 2016, 9:50 AM — Zacks
Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Friday, April 8, 2016, 1:35 PM — Zacks
Intercept (ICPT) Up Ahead of Advisory Committee Meeting
Wednesday, April 6, 2016, 9:10 AM — Zacks
Valeant Completes Accounting Review of Philidor, Shares Up
Wednesday, April 6, 2016, 8:30 AM — Zacks
Shire (SHPG) Wins Lialda Patent Trial vs. Allergan
Wednesday, March 30, 2016, 2:45 PM — Zacks
Keryx Up on Positive Auryxia Data in Iron Deficiency Anemia
Wednesday, March 30, 2016, 1:20 PM — Zacks
Valeant CEO Gets Subpoena from Senate Aging Committee
Tuesday, March 29, 2016, 2:45 PM — Zacks
Roche Files for FDA Approval of Elecsys BRAHMS Assay
Thursday, March 24, 2016, 7:30 AM — Zacks
Valeant to Get a New CEO Amid Turmoil, Ackman on Board
Tuesday, March 22, 2016, 10:40 AM — Zacks
McKesson (MCK) to Restructure Operations, Lower Headcount
Monday, March 21, 2016, 3:28 PM — Zacks
Walgreens Buys AmerisourceBergen Shares per Warrants
Monday, March 21, 2016, 3:24 PM — Zacks
UCB and Amgen Report Positive Data on Osteoporosis Drug
Monday, March 21, 2016, 2:40 PM — Zacks
Valeant Terminates Litigation with R&O Pharmacy
Thursday, March 10, 2016, 4:09 PM — Zacks
Sucampo Beats Earnings & Revenues on Strong Amitiza Sales
Wednesday, March 9, 2016, 9:42 AM — Zacks
New Strong Buy Stocks for March 3rd
Thursday, March 3, 2016, 9:04 AM — Zacks
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q4
Thursday, March 3, 2016, 8:20 AM — Zacks
ArQule (ARQL) Shows Strength: Stock Adds 7.6% in Session
Friday, February 19, 2016, 7:15 AM — Zacks
ArQule's Drug Gets Orphan Drug Status for Proteus Syndrome
Wednesday, November 18, 2015, 3:12 PM — Zacks
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Tuesday, April 21, 2015, 10:48 AM — Zacks
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Tuesday, April 21, 2015, 7:30 AM — Zacks
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Thursday, April 9, 2015, 7:30 AM — Zacks
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Thursday, April 2, 2015, 7:30 AM — Zacks
Zacks Rank #1 Additions for Friday - Tale of the Tape
Friday, March 13, 2015, 7:30 AM — Zacks
Can The Uptrend Continue for ArQule (ARQL)? - Tale of the Tape
Thursday, March 12, 2015, 6:08 AM — Zacks
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Tuesday, December 23, 2014, 8:30 AM — Zacks
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Wednesday, December 10, 2014, 8:30 AM — Zacks
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Thursday, December 4, 2014, 8:30 AM — Zacks
Can the Uptrend Continue for ArQule (ARQL)? - Tale of the Tape
Friday, November 28, 2014, 5:36 AM — Zacks
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Tuesday, November 18, 2014, 8:30 AM — Zacks
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Tuesday, November 11, 2014, 7:30 AM — Zacks
ArQule Posts Narrower-than-Expected Q1 Loss - Analyst Blog
Thursday, May 8, 2014, 11:58 AM — Zacks
ArQule's Loss Narrows in Q4 - Analyst Blog
Thursday, March 6, 2014, 12:37 PM — Zacks
Data on ArQule's Tivantinib - Analyst Blog
Wednesday, February 5, 2014, 4:40 PM — Zacks
ArQule (ARQL) Jumps: Stock Rises 6.8% - Tale of the Tape
Monday, January 20, 2014, 8:18 AM — Zacks
ArQule Up on Study Results - Analyst Blog
Friday, January 17, 2014, 5:04 PM — Zacks
RedHill Biopharma Sells ADS - Analyst Blog
Tuesday, December 31, 2013, 5:09 PM — Zacks
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Tuesday, December 31, 2013, 8:30 AM — Zacks
ArQule, Inc. Enters Oversold Territory - Tale of the Tape
Wednesday, December 18, 2013, 7:35 AM — Zacks
ARQL is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

CMN News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ARQL News | | Copyright © 2013 - 2017, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.